Sutro Biopharma, Inc. announced a collaboration with Sanofi Pasteur Limited to produce two undisclosed vaccine candidates. This collaboration highlights the potential value of Sutro's biochemical synthesis technology for the production of vaccines and provides additional validation of the benefits of the company's technology platform.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.16 USD | +5.05% | +42.47% | -3.03% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.03% | 340M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- STRO Stock
- News Sutro Biopharma, Inc.
- Sutro Biopharma to Collaborate with Sanofi Pasteur on Novel Production Approach for Vaccine Candidates